Home » USA Broker Ratings » Mylan N.V. – Consenus Indicates Potential 56.2% Upside

Mylan N.V. – Consenus Indicates Potential 56.2% Upside

Mylan N.V. with ticker code (MYL) have now 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 47 and 22 calculating the average target price we see 31.56. Given that the stocks previous close was at 20.21 this indicates there is a potential upside of 56.2%. The 50 day moving average now sits at 25.89 and the 200 day moving average is 29.23. The company has a market capitalisation of $10,274m. Visit the company website at: http://www.mylan.com

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Join us on our new LinkedIn page

Follow us on LinkedIn